Last quarter (Q ), Concert Pharma's total revenue was $8.00K, a decrease of -98.53% from the same quarter last year. In Q, Concert Pharma's net income was $-28.90M. See Concert Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18	Dec 17
Total Revenue	$ 42.00K	$ 32.58M	$ 7.90M	$ 1.08M	$ 10.51M	$ 143.89M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 124.31M	$ 110.09M	$ 80.55M	$ 80.09M	$ 66.09M	$ 51.24M
Operating Income	$ -124.27M	$ -77.51M	$ -72.65M	$ -79.02M	$ -55.58M	$ 92.65M
Net Non Operating Interest Income Expense	-	-	$ -2.20M	$ 849.00K	$ 0.00	$ -815.00K
Other Income Expense	$ -2.04M	$ -2.54M	$ -2.20M	$ 849.00K	$ -127.00K	$ 3.50M
Pretax Income	$ -126.31M	$ -80.05M	$ -74.85M	$ -78.17M	$ -55.71M	$ 95.34M
Tax Provision	-	$ 0.00	$ -85.00K	$ 0.00	$ 313.00K	$ -300.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -126.31M	$ -80.05M	$ -74.77M	$ -78.17M	$ -56.02M	$ 95.19M
Basic EPS	$ -3.21	$ -2.33	$ -2.40	$ -3.29	$ -2.40	$ 4.20
Diluted EPS	$ -3.21	$ -2.33	$ -2.40	$ -3.29	$ -2.40	$ 4.06
Basic Average Shares	$ 163.12M	$ 34.41M	$ 31.20M	$ 23.74M	$ 23.37M	$ 22.64M
Diluted Average Shares	$ 163.12M	$ 34.41M	$ 31.20M	$ 23.74M	$ 23.37M	$ 23.44M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 124.31M	$ 110.09M	$ 80.55M	$ 80.09M	$ 66.09M	$ 51.24M
Net Income From Continuing And Discontinued Operation	$ -126.31M	$ -80.05M	$ -74.77M	$ -78.17M	$ -56.02M	$ 95.64M
Normalized Income	$ -124.27M	$ -77.51M	$ -72.56M	$ -79.00M	$ -55.92M	$ 95.70M
Interest Expense	-	-	-	-	$ 0.00	$ 815.00K
EBIT	$ -124.27M	$ -77.51M	$ -72.65M	$ -79.02M	$ -55.58M	$ 96.15M
EBITDA	$ -123.00M	$ -76.03M	$ -71.04M	$ -77.35M	$ -54.34M	$ 97.16M

Currency in USD

Concert Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing